Johnson & Johnson (NYSE:JNJ) Shares Bought by Bell & Brown Wealth Advisors LLC

Bell & Brown Wealth Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,770 shares of the company’s stock after acquiring an additional 92 shares during the period. Bell & Brown Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $452,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its position in shares of Johnson & Johnson by 18.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares during the last quarter. FMR LLC raised its position in shares of Johnson & Johnson by 20.8% during the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the last quarter. GQG Partners LLC raised its position in shares of Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in shares of Johnson & Johnson by 52.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after purchasing an additional 2,093,392 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Johnson & Johnson by 37.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Citigroup lifted their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Sanford C. Bernstein lowered their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price for the company. Atlantic Securities lowered their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Wednesday, October 19th. Finally, Barclays assumed coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price for the company. Seven research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $182.42.

Johnson & Johnson Stock Down 0.2 %

Shares of NYSE JNJ opened at $174.88 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $457.22 billion, a PE ratio of 24.36, a P/E/G ratio of 3.45 and a beta of 0.56. The firm has a fifty day moving average of $176.22 and a 200-day moving average of $171.59. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. The business had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.60 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.58%. Johnson & Johnson’s payout ratio is 62.95%.

Johnson & Johnson announced that its Board of Directors has initiated a share repurchase plan on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Hait sold 15,000 shares of the business’s stock in a transaction on Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the completion of the transaction, the insider now owns 80,236 shares in the company, valued at approximately $13,764,485.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 300,750 shares of company stock worth $52,311,677. 0.35% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.